^
    5d
    Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study. (PubMed, Cancer)
    Momelotinib demonstrated meaningful clinical benefit and acceptable safety in cytopenic patients pretreated with ruxolitinib, which supports its role after ruxolitinib failure.
    Retrospective data • Journal • Real-world evidence
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    9d
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    11d
    ATLAS: A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (clinicaltrials.gov)
    P2/3, N=192, Not yet recruiting, GlaxoSmithKline
    New P2/3 trial
    |
    Ojjaara (momelotinib)
    17d
    A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | N=53 --> 220
    Enrollment change • First-in-human • CALR
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    17d
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | N=56 --> 80
    Enrollment change
    |
    Ojjaara (momelotinib)
    25d
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | N=59 --> 80 | Trial completion date: Mar 2029 --> Dec 2027
    Enrollment change • Trial completion date
    |
    Ojjaara (momelotinib)
    26d
    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. (PubMed, Blood Neoplasia)
    In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.
    Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    27d
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)
    1m
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=59, Recruiting, GlaxoSmithKline | N=45 --> 59
    Enrollment change
    |
    Ojjaara (momelotinib)
    1m
    RNA dicing promotes the expression of an oncogenic JAK1 isoform. (PubMed, Cell Rep)
    This results in a better response to the JAK1 inhibitor momelotinib, highlighting RNA dicing's role in patient stratification. Our findings show that RNA dicing diversifies mRNA products, significantly impacting biological functions.
    Journal
    |
    IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    1m
    Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics. (PubMed, Cell Death Dis)
    The CDK4/6 inhibitors abemaciclib and palbociclib have demonstrated promising results in patient-derived xenograft models of PM...While some cells showed sensitivity to Bcl-xL inhibitors, neither navitoclax nor the specific Bcl-xL inhibitor A-1331852, nor other BH3 mimetics targeting Bcl-2 (venetoclax) or Mcl-1 (S63845) increased cell death when combined with palbociclib...Therefore, we employed inhibitors of these pathways, such as dasatinib, momelotinib or Torin-1, which did not synergise with palbociclib to kill the cells...The differential effects of palbociclib and cisplatin on permanent growth arrest were verified by sorting PM cells based on size and β-galactosidase activity. Our findings underscore the importance of understanding the nature of therapy-induced senescence when assessing the effectiveness of senolytics in different tumour models.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Venclexta (venetoclax) • cisplatin • Ibrance (palbociclib) • dasatinib • Verzenio (abemaciclib) • navitoclax (ABT 263) • S63845 • A-1331852 • Ojjaara (momelotinib) • Torin1
    2ms
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)